Lumira Ventures partners with exceptional entrepreneurs to build life science companies that transform the lives of patients worldwide.
July 9, 2020
With a surge in new cases surpassing daily highs across the US, it is clear that the battle against COVID-19 will continue for the foreseeable future. While much of the world tries to go back to... Learn More
UCB Acquires Engage Therapeutics: Staccato® Alprazolam – A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy
June 5, 2020
- Staccato® Alprazolam could be a potential solution for 20-30% of epilepsy patients - Initial upfront payment of US$ 125 million and further potential milestone payments of up to US$ 145... Learn More
Forbius Reported Safety and Initial Anti-Fibrotic Effects of First-in-Class, Selective TGF-beta Inhibitor, AVID200, in Phase 1b Systemic Sclerosis Trial at EULAR 2020
June 5, 2020
Initial results demonstrate anti-fibrotic effects of AVID200 as indicated by rapid and sustained declines in skin fibrosis.AVID200 was well-tolerated, and no dose-limiting toxicities, SAEs or... Learn More
Our investment team of 9 professionals has over 225 years of collective experience founding, managing and investing in healthcare and life sciences companies. We value collaboration, creativity and challenging conventional wisdom.
Lumira donates a portion of partner time and profits to support the research, translational medicine and healthcare access missions of over a dozen leading healthcare foundations.
“Lumira’s philanthropic vision of leveraging research, resources and knowledge to improve the lives of patients will strengthen St. Michael’s ability to accelerate the pace.”
Dr. Arthur Slutsky | Vice-President
Vice-President of Research at St. Michael’s Hospital
“Lumira’s model provides a new pathway for philanthropy to partner with investors in advancing healthcare innovation.”
Barbara Grantham | President & Ceo
VGH & UBC Hospital Foundation
“This distinctive approach to supporting innovation is very creative, very much needed and very much appreciated by Princess Margaret and University Health Network.”
Paul Alofs | President & Ceo
Princess Margaret Cancer Foundation
Our team is strategically situated across North America to identify innovative companies within and outside the traditional start-up hubs, and help them access capital, talent and strategic partners.
141 Adelaide Street
Canada, M5H 3L5
3, Place Ville Marie
Bureau 12350, Niveau L
Canada, H3B 0E7
1021 West Hastings Street,
Canada, V6E 0C3
303 Wyman Street